Background In two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, reduced
disease progression, as measured by the decline in forced vital capacity (FVC) or vital …

Pirfenidone is an antifibrotic agent that has been evaluated in three multinational phase 3
trials in patients with idiopathic pulmonary fibrosis (IPF). We analysed pooled data from the …

Background Pirfenidone is an oral antifibrotic agent that has been shown to reduce the
decline in lung function in patients with idiopathic pulmonary fibrosis (IPF). We performed an …

Idiopathic pulmonary fibrosis (IPF) is a fatal disorder without an effective therapy to date. In a
double-blind, randomized, placebo-controlled trial, 107 patients were prospectively …

Background Idiopathic pulmonary fibrosis (IPF) is a chronic fibrotic lung disease with a
median survival of 2–5 years and limited treatment options. In 2008, pirfenidone became the …

Idiopathic pulmonary fibrosis (IPF) is a chronic, irreversible, progressively destructive lung
disease that culminates in respiratory failure and death. Randomised controlled trials have …

Background and objective Pirfenidone is an oral antifibrotic agent that is approved in several
countries for the treatment of idiopathic pulmonary fibrosis (IPF). We performed a …

Idiopathic pulmonary fibrosis (IPF) is a devastating chronic fibrotic lung disease. Although
the precise cause of the disease is still unknown, recent studies have shown that the …

Background Patients with idiopathic pulmonary fibrosis (IPF) demonstrate a range of lung
function impairment. However, the efficacy of antifibrotics compared with placebo has not …

Backgroud Previous pirfenidone trials have only involved patients with mild-to-moderate
idiopathic pulmonary fibrosis (IPF). The aim of this study was to investigate the safety and …